BIOCRYST PHARMACEUTICALS INC (BCRX) Institutional Ownership Changes & 13F Activity
BIOCRYST PHARMACEUTICALS INC (BCRX). Institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC Form 13F filings (Q2 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions in the latest reporting period. Notable filers include Royalty Pharma Sub-Manager, Llc, Millennium Management Llc, Kynam Capital Management, Lp, Perceptive Advisors Llc, and Jane Street Group, Llc.
| Institution | Type | Change in shares | Change Position % | Shares | Reported stock balance | Portfolio quarter | Filing date |
|---|---|---|---|---|---|---|---|
| Manufacturers Life Insurance Company, The | Buy | +17,474 | +17.1% | 119,516 | $1.20M | Q2 2026 | Sep 09, 2026 |
| Integrated Wealth Concepts Llc | Buy | +10,778 | — | 10,778 | $107.78K | Q2 2026 | Sep 09, 2026 |
| Citadel Advisors Llc | Buy | +740,417 | +72.7% | 1,759,160 | $17.59M | Q2 2026 | Sep 02, 2026 |
| Corient Private Wealth Llc | Buy | +54,980 | +57.6% | 150,447 | $1.50M | Q2 2026 | Aug 27, 2026 |
| California State Teachers Retirement System | Sell | -7,115 | -2.8% | 251,230 | $2.51M | Q2 2026 | Aug 24, 2026 |
| Royalty Pharma Sub-Manager, Llc | Sell | -3,846,154 | -100.0% | 0 | $0.00 | Q2 2026 | Aug 21, 2026 |
| Assenagon Asset Management S.A. | Buy | +120,097 | +51.6% | 353,044 | $3.53M | Q2 2026 | Aug 21, 2026 |
| Nantahala Capital Management, Llc | Sell | -86,237 | -4.3% | 1,901,160 | $19.01M | Q2 2026 | Aug 19, 2026 |
| Mercer Global Advisors Inc | Buy | +51,453 | +513.6% | 61,472 | $614.72K | Q2 2026 | Aug 19, 2026 |
| Seven Fleet Capital Management Lp | Sell | -51,469 | -50.2% | 51,024 | $510.24K | Q2 2026 | Aug 17, 2026 |
| Millennium Management Llc | Buy | +3,207,008 | +1708.4% | 3,394,729 | $33.95M | Q2 2026 | Aug 14, 2026 |
| Kynam Capital Management, Lp | Sell | -3,158,135 | -55.6% | 2,522,660 | $25.23M | Q2 2026 | Aug 14, 2026 |
| Perceptive Advisors Llc | Buy | +2,874,855 | +38.7% | 10,308,888 | $103.09M | Q2 2026 | Aug 14, 2026 |
| Jane Street Group, Llc | Buy | +2,140,076 | +343.7% | 2,762,683 | $27.63M | Q2 2026 | Aug 14, 2026 |
| Goldman Sachs Group Inc | Buy | +2,134,431 | +90.9% | 4,481,874 | $44.82M | Q2 2026 | Aug 14, 2026 |
| Aqr Capital Management Llc | Buy | +1,774,161 | +403.1% | 2,214,302 | $22.14M | Q2 2026 | Aug 14, 2026 |
| Susquehanna International Group, Llp | Sell | -1,619,653 | -57.5% | 1,195,651 | $11.96M | Q2 2026 | Aug 14, 2026 |
| Vestal Point Capital, Lp | Buy | +1,275,000 | +18.1% | 8,300,000 | $83.00M | Q2 2026 | Aug 14, 2026 |
| Invesco Ltd. | Buy | +1,233,783 | — | 1,233,783 | $12.34M | Q2 2026 | Aug 14, 2026 |
| Eversept Partners, Lp | Sell | -1,174,167 | -38.6% | 1,865,653 | $18.66M | Q2 2026 | Aug 14, 2026 |
| Hrt Financial Lp | Buy | +1,081,523 | — | 1,081,523 | $10.81M | Q2 2026 | Aug 14, 2026 |
| Moore Capital Management, Lp | Buy | +848,336 | — | 848,336 | $8.48M | Q2 2026 | Aug 14, 2026 |
| Schonfeld Strategic Advisors Llc | Sell | -626,877 | -46.9% | 710,816 | $7.11M | Q2 2026 | Aug 14, 2026 |
| Man Group Plc | Sell | -560,433 | -43.3% | 732,867 | $7.33M | Q2 2026 | Aug 14, 2026 |
| Exoduspoint Capital Management, Lp | Buy | +554,859 | +291.9% | 744,917 | $7.45M | Q2 2026 | Aug 14, 2026 |
| Pdt Partners, Llc | Sell | -538,951 | -95.7% | 24,489 | $244.89K | Q2 2026 | Aug 14, 2026 |
| Elmind Capital, Lp | Sell | -480,000 | -48.0% | 520,000 | $5.20M | Q2 2026 | Aug 14, 2026 |
| Sphera Funds Management Ltd. | Sell | -444,413 | -51.3% | 422,051 | $4.22M | Q2 2026 | Aug 14, 2026 |
| Orbimed Advisors Llc | Buy | +426,800 | +29.9% | 1,852,000 | $18.52M | Q2 2026 | Aug 14, 2026 |
| Two Sigma Investments, Lp | Buy | +382,721 | +6.0% | 6,775,349 | $67.75M | Q2 2026 | Aug 14, 2026 |
Frequently asked questions about BCRX activity
Which institutional owners are buying BCRX?
Institutional owners buying BCRX include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in BCRX activity?
"Buy" means an investor increased their reported position in BCRX compared to the prior reporting period. This reflects growing exposure to BIOCRYST PHARMACEUTICALS INC (BCRX) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in BCRX increasing?
Institutional interest in BCRX can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.
Related BCRX Institutional Insights
- BCRX Overview
- BCRX 13F Institutional Holders
- BCRX Top Institutional Shareholders
- Healthcare Sector Institutional Ownership
- Healthcare Sector Portfolio Overlap
- Institutional Portfolio Overlap & Shared Holdings
- Most Bought Healthcare Stocks By Institutional Investors
- Most Sold Healthcare Stocks By Institutional Investors
- BCRX Insider Trading & SEC Form 4 Activity
- BCRX Articles
- Top Institutional Investor Stock Rankings